CM&R Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Medicine & Research
Volume 3, Number 3 : 137 -145
doi:
© 2005 Marshfield Clinic
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hillman, M. A.
Right arrow Articles by Burmester, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hillman, M. A.
Right arrow Articles by Burmester, J. K.

Original Research

A Prospective, Randomized Pilot Trial of Model-Based Warfarin Dose Initiation using CYP2C9 Genotype and Clinical Data

Michael A. Hillman, MD, MBA, Russell A. Wilke, MD, PhD, Steven H. Yale, MD, Humberto J. Vidaillet, MD, Michael D. Caldwell, MD, PhD, Ingrid Glurich, PhD, Richard L. Berg, MS, John Schmelzer, PhD and James K. Burmester, PhD

Michael A. Hillman, MD, MBA, Department of Care Management, Marshfield Clinic, Marshfield, Wisconsin
Russell A. Wilke, MD, PhD, Department of Internal Medicine, Marshfield Clinic, Marshfield, Wisconsin and Center for Human Genetics, Marshfield Clinic Research Foundation, Marshfield, Wisconsin
Steven H. Yale, MD, Department of Internal Medicine, Marshfield Clinic, Marshfield, Wisconsin and Clinical Research Center, Marshfield Clinic Research Foundation, Marshfield, Wisconsin
Humberto J. Vidaillet, MD, Department of Cardiology, Marshfield Clinic, Marshfield, Wisconsin
Michael D. Caldwell, MD, PhD, Department of Surgery, Marshfield Clinic, Marshfield, Wisconsin
Ingrid Glurich, PhD and James K. Burmester, PhD, Center for Human Genetics, Marshfield Clinic Research Foundation, Marshfield, Wisconsin
Richard L. Berg, MS, Biostatistics and Bioinformatics, Marshfield Clinic Research Foundation, Marshfield, Wisconsin
John Schmelzer, PhD, Health Services Research Center, Marshfield Clinic Research Foundation, Marshfield, Wisconsin

Reprint Requests: Russell A. Wilke, MD, PhD, Center for Human Genetics, Marshfield Clinic Research Foundation, 1000 North Oak Avenue, Marshfield, WI 54449. Tel: 715-387-9433; Fax: 715-389-4950; Email: wilke.russell{at}mcrf.mfldclin.edu.

Background: Rapid genetic screening for cytochrome P450 (CYP) 2C9 variants may play a role in improving the efficacy and safety of warfarin in individuals with CYP2C9 variants. The feasibility of prospective CYP2C9 model-based warfarin dosing has not yet been assessed.

Objectives: To evaluate the feasibility of applying a CYP2C9 gene-based warfarin dosing model in clinical practice.

Design: Prospective, randomized, single-blinded clinical pilot trial.

Setting: Large multispecialty group practice.

Patients: Candidates were recruited from a list of clinic patients eligible for warfarin initiation. This included patients with newly diagnosed thromboembolic disease or atrial arrhythmia, as well as patients anticipating elective valvuloplasty or arthroplasty. Patients who previously received warfarin were excluded.

Interventions: Subjects were randomized to receive either 1) a standard initiation dose of 5 mg warfarin/day, or 2) rapid CYP2C9 genotyping and an initiation dose determined using parameters estimated from a previously published multivariate model [including age, body size, co-morbidity (e.g., diabetes), clinical indication (e.g., valvuloplasty) and CYP2C9 genotype].

Measurements: Primary outcome measurements were patient willingness to participate, physician willingness to refer, sample processing time, ability to administer calculated dosage and adequacy of follow-up.

Limitations: This pilot trial was designed to assess the feasibility of model-based warfarin dosing. Power was insufficient for statistical comparison of adverse event rates.

Results: Forty-three of 117 patients had no prior warfarin treatment and were eligible. Five declined to participate. Twenty patients were randomized to a standard initiation dose of 5 mg daily. Eighteen patients were randomized to model-based dosing. All but one participant received the assigned initiation dose. Blood draw to dosage calculation time (including genotyping) required approximately 4 hours. Six adverse events occurred within the standard dosing group, and two adverse events occurred within the model-based dosing group.

Conclusions: Prospective application of a multivariate CYP2C9 gene-based warfarin dosing model is feasible.

Key Words: Adverse events • Anticoagulation • Cytochrome P450 • CYP2C9 • Warfarin • Multivariate dosing models • Genetic screening




This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
L. M Hynicka, W. D Cahoon Jr, and B. L Bukaveckas
Genetic Testing for Warfarin Therapy Initiation
Ann. Pharmacother., September 1, 2008; 42(9): 1298 - 1303.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti
Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 160S - 198S.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. D. Caldwell, T. Awad, J. A. Johnson, B. F. Gage, M. Falkowski, P. Gardina, J. Hubbard, Y. Turpaz, T. Y. Langaee, C. Eby, et al.
CYP4F2 genetic variant alters required warfarin dose
Blood, April 15, 2008; 111(8): 4106 - 4112.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. L. Anderson, B. D. Horne, S. M. Stevens, A. S. Grove, S. Barton, Z. P. Nicholas, S. F.S. Kahn, H. T. May, K. M. Samuelson, J. B. Muhlestein, et al.
Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation
Circulation, November 27, 2007; 116(22): 2563 - 2570.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
M. D. Caldwell, R. L. Berg, K. Q. Zhang, I. Glurich, J. R. Schmelzer, S. H. Yale, H. J. Vidaillet, and J. K. Burmester
Evaluation of Genetic Factors for Warfarin Dose Prediction
Clin. Med. Res., March 1, 2007; 5(1): 8 - 16.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
Y. M. Kim, S. H. Yoo, R. Y. Kang, M. J. Kim, Y. Y. Bae, Y. K. Lee, S. J. Jeon, K. J. Chon, S. M. Shin, S. G. Kim, et al.
Identifying drugs needing pharmacogenetic monitoring in a Korean hospital
Am. J. Health Syst. Pharm., January 15, 2007; 64(2): 166 - 175.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
H. Oberwittler, A. Hirschfeld-Warneken, R. Wesch, H. Willerich, L. Teichert, K.-H. Lehr, R. Ding, W. E. Haefeli, and G. Mikus
Significant Pharmacokinetic and Pharmacodynamic Interaction of Warfarin With the NO-Independent sGC Activator HMR1766
J. Clin. Pharmacol., January 1, 2007; 47(1): 70 - 77.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
C. R. Lee
Warfarin Initiation and the Potential Role of Genomic-Guided Dosing
Clin. Med. Res., November 1, 2005; 3(4): 205 - 206.
[Full Text] [PDF]

Home page
 Clin Med ResHome page
R. A. Wilke, R. L. Berg, H. J. Vidaillet, M. D. Caldwell, J. K. Burmester, and M. A. Hillman
Impact of Age, CYP2C9 Genotype and Concomitant Medication on the Rate of Rise for Prothrombin Time During the First 30 Days of Warfarin Therapy
Clin. Med. Res., November 1, 2005; 3(4): 207 - 213.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by Marshfield Clinic.